Asset Dedication LLC Has $3.23 Million Stake in Johnson & Johnson $JNJ

Asset Dedication LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 24.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,410 shares of the company’s stock after acquiring an additional 3,473 shares during the quarter. Asset Dedication LLC’s holdings in Johnson & Johnson were worth $3,228,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its stake in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. United Bank increased its position in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. lifted its position in Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock valued at $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. boosted its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after purchasing an additional 6,584 shares during the period. Institutional investors own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves ICOTYDE (icotrokinra), J&J’s once‑daily oral IL‑23R targeted peptide for moderate‑to‑severe plaque psoriasis — a first‑in‑class oral alternative to leading injectable IL‑23 therapies that could expand patient access and drive new prescription revenue. US FDA approves J&J’s oral psoriasis pill
• Positive Sentiment: HSBC raised its JNJ price target to $280 (from $265) and reiterated a Buy, citing healthcare strength and likely improved near‑term fundamentals — this adds analyst support and gives upside cushion relative to current levels. HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target
• Neutral Sentiment: Analyst commentary and comparisons (e.g., J&J vs Merck) highlight relative strengths/risks across pipelines and cash flows — useful context but not an immediate catalyst. J&J or Merck? Key Factors Investors Must Weigh Right Now
• Neutral Sentiment: Market watchlists and “stocks to watch” mentions raise visibility but don’t change fundamentals immediately. 4 stocks to watch on Wednesday: T, M, MU, JNJ
• Negative Sentiment: Shares recently pulled back (reports of a slide and lower intraday volume) indicating short‑term profit‑taking despite the positive drug news and analyst upgrade; that pressure likely explains the stock trading down today. Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Leerink Partners increased their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, March 5th. Finally, Morgan Stanley set a $253.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $236.17.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,142 shares of company stock valued at $7,360,528 in the last three months. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.4%

Johnson & Johnson stock opened at $237.15 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market capitalization of $571.21 billion, a P/E ratio of 21.46, a PEG ratio of 2.35 and a beta of 0.34. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The stock has a 50-day simple moving average of $233.95 and a 200 day simple moving average of $207.76.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.